

ISSN Print: 2617-4693 ISSN Online: 2617-4707 NAAS Rating (2025): 5.29 IJABR 2025; SP-9(8): 06-08 www.biochemjournal.com Received: 05-05-2025 Accepted: 10-06-2025

Balusupati Indhuteja

M.V.Sc., Scholar, Department of Veterinary Medicine, College of Veterinary Science, PVNR Telangana Veterinary University, Hyderabad, Telangana, India

Gadige Ambica

Associate Professor & Head and Corresponding Author, Department of Veterinary Clinical Complex, College of Veterinary Science, Mamnoor, Warangal, Telangana, India

Karlapudi Satishkumar

Professor of Veterinary Medicine & Dean of Student Affairs, PVNR Telangana Veterinary University, Hyderabad, Telangana, India

Bobbili Rajendar

Associate Professor,
Department of Veterinary
Pharmacology & Toxicology,
College of Veterinary Science,
PVNR Telangana Veterinary
University, Hyderabad,
Telangana, India

Corresponding Author: Gadige Ambica

Associate Professor & Head and Corresponding Author, Department of Veterinary Clinical Complex, College of Veterinary Science, Mamnoor, Warangal, Telangana, India

Evaluating the efficacy of homeopathic drug treatment in canine distemper: Associated encephalitis

Balusupati Indhuteja, Gadige Ambica, Karlapudi Satishkumar and Bobbili Rajendar

DOI: https://www.doi.org/10.33545/26174693.2025.v9.i8Sa.5081

Abstract

The present study was conducted during the period from February to September, 2024 at the Department of Veterinary Medicine, College of Veterinary Science, Rajendranagar, Hyderabad, to evaluate the efficacy of *Cicuta virosa* a homeopathic drug on alleviating clinical signs and haemato-biochemical parameters in dogs with canine distemper (CD)-induced encephalitis. Twelve dogs of various age groups, confirmed with CD-associated neurological involvement, were randomly assigned into two treatment groups (n = 6 per group). Group I received oral supplementation of *Cicuta virosa* 30C drops in combination with a conventional treatment protocol, while Group II was treated with the conventional protocol alone. Clinical observations and haemato-biochemical analyses were performed to assess treatment outcomes. Group I showed significantly greater improvement in clinical signs and normalization of haemato-biochemical parameters compared to Group II, with statistical significance at p < 0.01. The findings indicate that *Cicuta virosa* 30C, when used as an adjunct to standard therapy, may enhance recovery and improve clinical outcomes in dogs suffering from CD-induced encephalitis.

Keywords: Canine distemper, encephalitis, haemato biochemistry and treatment

Introduction

Encephalitis is defined as inflammation of the brain parenchyma, which can result from a variety of infectious and non-infectious causes (Arulselvam et al., 2022). Clinically, encephalitisis often characterized by a range of neurological signs, including convulsions, nystagmus, depression, head and neck deviation, circling, incoordination, photophobia, hypersalivation, muscle tremors, ataxia, postural abnormalities, complete paralysis, and seizures. While each of these signs can occur in other neurological conditions, their simultaneous presence strongly suggests encephalitic involvement. Canine Distemper, a Virus infection frequently leads to severe neurological complications in affected dogs. The virus replicates in neurons and glial cells, producing lesions in the grey matter and causing demyelination. These pathological changes result in tissue damage and provoke an inflammatory response within the central nervous system, ultimately manifesting as The prognosis for dogs exhibiting the neurological form of canine distemper is generally poor. Although some animals may survive, they often experience long term neurological deficits. Management primarily relies on supportive therapy and symptomatic treatment. Anticonvulsant drugs, such as phenobarbital, are commonly employed to control seizures and other neurological manifestations. However, prolonged use of these medications can lead to adverse effects including lethargy, incoordination, polyphagia, weight gain, and hepatic complications (Geetha and Selvaraju, 2019) [7]. In recent years, interest has grown in the use of natural and alternate vet therapies, including herbal extracts and homeopathic medicines for the management of neurological disorders. Some of these agents have demonstrated promising anticonvulsant and neuro protective properties with relatively fewer side effects (Huang et al., 2020) [10]. Nevertheless, scientific literature on the application of homeopathic treatments specifically targeting neurological signs in canine distemper remains scarce. However, there is a need to further explore their clinical efficacy and potential mechanisms of action. In light of these considerations, the present study was undertaken to evaluate the therapeutic efficacy of the homeopathic remedy Cicuta virosa 30C, in combination with conventional therapy, for managing clinical signs and haematobiochemical alterations in dogs affected by CDV-induced encephalitis.

2. Materials and Methods

The present research work was done during the period from February to September, 2024 and following materials and methods were used. The study population consisted of client-owned dogs presented to Department of Veterinary Clinical Complex, College of Veterinary Science, Rajendranagar, Hyderabad with the history of recurrent seizures, neurological signs, and ataxia. These dogs were subjected to detailed neurological examination, anamnesis, and clinical evaluation, and were selected for the study. However, six apparently healthy dogs were also chosen at random as healthy control group. The clinical material collected from both CD affected and apparently healthy dogs were nasal swabs, blood serum samples were collected and analysed using Haematology analyser, biochemical analyser, electro cardiogram, electro encephalogram. Therapeutic agents used in this study were inj. Cefotaxim @ 20 mg/kg, Ondansetron @ 0.2 mg/kg, Mecobalmin syrup, Phenobarbitone @ 4 mg/kg, Ranitidine @ 2 mg/kg and Homeopathic Drug Cicuta @ 5 drops QUID. For data analysis One-way ANOVA was done by using Statistical Package for them Social Sciences (SPSS) version 10. To compare the means, Duncan's multiple comparison test was used, with significance levels set at 5% (p<0.05) and 1% (p<0.01) and the results are presented as mean±standard error.

3. Results and Discussion

3.1 Therapeutic protocol

Twelve dogs diagnosed with CDE were randomly assigned into two treatment groups (n=6 each). Group I received homeopathic preparation, Cicuta virosa 30C drops @ 5drops four times daily, in addition to conventional symptomatic treatment. Whereas, Group II received Phenobarbitone @ 4 mg/kg orally alongside the same conventional treatment. Conventional therapy included Inj. Cefotaxime @ 20 mg/kg i.v or I.m, Inj. Ringers Lactate @ 10 ml/kg i.v, Inj. Ondansetron @ 0.2 mg/kg i.v, Ranitidine @ 2 mg/kg s.c and Syrup Neurokind pet oral. Cicuta virosa, traditionally used in the treatment of seizures and neuromuscular disturbances, contains cicutoxin, a compound known to modulate GABAergic neuro transmission and potassium channel conductance (Geetha and Selvaraju, 2019; Madaan and Kumar, 2012) [7, 16]. The homeopathic remedy showed marked improvement in clinical symptoms such as flexor spasms, chorea, and myoclonus, consistent with its reported antiepileptic potential. In contrast, phenobarbitone, a standard antiepileptic drug, acts by enhancing GABA-mediated chloride influx into neurons, thereby suppressing seizure activity (Podell et al., 2015; Bhatti et al., 2015) [20, 2]. However, prolonged administration is often associated with side effects like lethargy, ataxia, and increased appetite (Geetha and Selvaraju, 2019) [7].

3.2 Therapeutic efficacy Evaluation

Therapeutic response was monitored over a one-month period based on seizure control. The percentage reduction in seizure frequency in Group 1 dogs before and after treatment was 4.18 ± 2.40 and 1.12 ± 0.06 episodes/day, respectively and with respect to percentage reduction in seizure duration before and after therapy was reported to be 3.14 ± 0.23 and 1.41 ± 0.22 minutes, respectively. Whereas, the percentage reduction in seizure frequency in Group II

dogs before and after treatment was 3.80 ± 1.51 and 2.08 ± 0.03 episodes/day, respectively and with respect to percentage reduction in seizure duration before and after therapy was reported to be 2.45 ± 0.27 and 0.55 ± 0.13 minutes, respectively.

Though clinical improvement was noticed in both the groups, Group I dogs which received homeopathic medication demonstrated a more substantial reduction in seizure frequency and better overall clinical recovery. The combined use of homeopathy and conventional therapy appeared to enhance therapeutic outcomes, possibly through synergistic effects on neural stabilization and inflammation control. These results are supported by previous research (Geetha and Selvaraju, 2019) [7], documented effective seizure management and improved neurological function in CDV-affected dogs treated with homeo medication, highlights the potential role of homeopathy as an adjunct therapeutic option in the management of canine distemper encephalitis, particularly in cases with prominent neurological involvement.

4. Conclusion

From the present study, it could be concluded that, though there was improvement in both the groups of CDE affected dogs, Group I dogs treated with homeopathic drug Cicuta drops showed faster recovery, thus revealed to be more efficacious and as it showed faster and complete improvement in clinical signs, seizures frequency and duration after therapy and therapeutic efficacy was reported to be significant (p<0.05).

5. References

- 1. Arulselvam V, Kamalakannan D, Arumugam AP, Narayanan D, Padmanadan V. Traumatic encephalitis in dogs. Small Animal Advances. 2022;1(2):33-35.
- 2. Bhatti SFM, De Risio L, Muñana K, Penderis J, Stein SM, Tipold A, *et al.* International Veterinary Epilepsy Task Force consensus proposal: medical treatment of canine epilepsy in Europe. BMC Vet Res. 2015;11:176.
- 3. Budaszewski R, Pinto LD, Weber MN, Caldart ET, Alves CDBT, Martella V, *et al.* Genotyping of canine distemper virus strains circulating in Brazil from 2008 to 2012. Virus Res. 2014;180:76-83.
- 4. Coates JR, Bergman RL. Seizures in young dogs and cats: pathophysiology and diagnosis. Seizure. 2005;5:18.
- 5. Daga M, Srivastava M, Singh AP, Ahuja A, Sharma A, Kachhawa JP, *et al.* Hematological alteration in canine distemper affected dogs. J Immunol Immunopathol. 2013;15(1):158.
- 6. Galán A, Gamito A, Carletti BE, Guisado A, Mulas JM, Pérez J, *et al.* Uncommon acute neurologic presentation of canine distemper in 4 adult dogs. Can Vet J. 2014;55:373-378.
- 7. Geetha M, Selvaraju G. Spectrum of clinical manifestations of canine distemper in dogs. Int J Curr Microbiol Appl Sci. 2019;8:1916-1920.
- 8. Headley SA, Graca DL. Canine distemper: epidemiological findings of cases. Braz J Vet Res Anim Sci. 2000;37:136-140.
- 9. Headley SA, Sukura A. Naturally occurring systemic canine distemper virus infection in a pup. Braz J Vet Pathol. 2009;2(2):95-101.

- Huang R, Zhu Y, Lin L, Song S, Cheng L, Zhu R. Solid lipid nanoparticles enhanced the neuroprotective role of curcumin against epilepsy through activation of Bcl-2 family and P38 MAPK pathways. ACS Chem Neurosci. 2020;11(13):1985-1995.
- 11. Jeserevics J, Viitmaa R, Cizinauskas S, Sainio K, Jokinen TS, Snellman M, *et al.* Electroencephalography findings in healthy and Finnish Spitz dogs with epilepsy: visual and background quantitative analysis. J Vet Intern Med. 2007;21:1299-1306.
- Jesus IS, Cruz AV, Santos CMP, Barra ECM, Costa JC, Monteiro TRM, et al. Molecular diagnosis and clinicopathological characteristics of canine distemper neurologic disease. Genet Mol Res. 2021;20(3):gmr18884.
- 13. Jozwik A, Frymus T. Natural distemper in vaccinated and unvaccinated dogs in Warsaw. J Vet Med B. 2002;49:413-414.
- 14. Latha D, Srinivasan SR, Thirunavukkarasu PS, Gunaselan L, Ramadass P, Narayanan RB. Assessment of canine distemper virus infection in vaccinated and unvaccinated dogs. Indian J Biotechnol. 2007;6:35-40.
- 15. Luo H, Li K, Zhang H. Epidemiology of canine distemper and canine parvovirus in pet dogs in Wenzhou, China. Indian J Anim Res. 2017;51(1):159-161.
- 16. Madaan R, Kumar S. Screening of alkaloid fraction of *Conium maculatum* L. aerial parts for analgesic and anti-inflammatory activity. Indian J Pharm Sci. 2012;74(5):457.
- 17. Mariscoli M, Jaggy A. Clinical and electroencephalographic findings of inflammatory and infectious diseases of the central nervous system in dogs: a retrospective study. J Vet Med B. 1997;44(1-10):1-8
- Nelson RW, Couto CG. Small Animal Internal Medicine. 4th ed. St. Louis: Mosby Elsevier; 2009. p. 1082-1083.
- 19. Pákozdy A, Thalhammer JG, Leschnik M, Halász P. Electroencephalographic examination of epileptic dogs. Vet Hung. 2012;60(3):309-324.
- 20. Podell M, Volk HA, Berendt M, Löscher W, Muñana K, Patterson EE, *et al.* Small Animal Consensus Statement on Seizure Management in Dogs. J Vet Intern Med. 2015;30:477-490.
- 21. Sharma M. Clinico-therapeutic studies on canine distemper [Master's thesis]. Palampur: Himachal Pradesh Krishi Vishvavidyalaya; 2017.
- 22. Stanciu GD, Musteață M, Solcan G. Analysis and evaluation of cerebral bioelectric behavior in dogs with epilepsy through electroencephalogram. Sci Works Ser C Vet Med. 2015;61(2):ISSN 2067-3663.
- 23. Tariq A, Shahzad A, Tahira S. Clinical aspects of canine distemper in 1.5-year-old Labrador retriever. Res J Vet Pract. 2013;1(2):20-22.
- 24. Yama T, Rajesh JB, Prasad H, Rajkhowa TK, Sarma K, Roy Choudhury P, *et al.* Scholarly view of canine distemper cases in Mizoram. Int J Curr Microbiol Appl Sci. 2020;9(9):3260-3266.
- 25. Zafar MS, Khan SA, Rabbani A. Haematological studies and estimation of electrolytes in dogs exhibiting diarrheal signs. Pak Vet J. 1999;19(1):35-39.